UPDRS

The most useful diagnostic tool is the clinical history, including both presenting symptoms and associated risk factors. The Unified Parkinson s Disease Rating Scale (UPDRS) is used to define the degree of disability. 

Coenzyme Q10 is an antioxidant essential for mitochondrial function. A dose of 1200 mg daily was associated with a slower decline in UPDRS scores than patients not receiving coenzyme Q10. Lower doses were no better than placebo, but the drug continues to be studied in doses up to 2400 mg daily. Many formulations contain vitamin E, and patients should not exceed recommended daily allowances of this vitamin, as bleeding times may be prolonged.42,43... 

Evaluate the clinical outcomes of treatment by using the UPDRS. In addition, periodically ask patients to record the amount of on and off time they have with and without dyskinesias in a diary. There are a variety of scales that can be used to assess QOL, depression, anxiety, and sleep disorders. Patients with PD cannot be cured but treatment can delay the progression of symptoms and improve QOL. Delaying the patient s admission into a nursing home is a good outcome. 

At the last visit, MW s fluoxetine was changed to bupropion, pergolide was started and gradually increased to 0.25 mg three times daily, and a dandruff shampoo was started. Since that time his skin condition, attitude, apathy, stiffness, rigidity, handwriting, tremor, slowness, and kicking have improved. The UPDRs score is 5 while "on". 

UPDRS Unified Parkinson s Disease Rating Scale... 

All of the more recent compounds have been tested in randomized double-blind clinical trials using the Unified Parkinson s Disease Rating Scale (UPDRS). We do not however have studies comparing the different drugs nor different treatment durations. In addition, the length of these trials is totally different from that of the natural disease course (20 years). It is paradoxical that levodopa, developed in the sixties, remains today the mainstay treatment for Parkinson s disease (levodopa is always associated with a peripheral decarboxylase inhibitor, either car-bidopa or benzerazide). 

United Parkinson Disease Rating Scale (UPDRS) useful for monitoring efficacy endpoints... 

Fahn S, Elton RL, UPDRS Development Committee (1987) Unified Parkinson s Disease Rating Scale. In Fahn S, Marsden CD, Goldstein M, Caine DB (Eds), Recent Developments in Parkinson s Disease, pp. 153-163. MacMillan Health Care Information, New York. 

In some cases, therefore, the linear model can be a reasonable approximation for disease progression when the disease is observed over a relatively short period of time or if the number of individuals experiencing complete recovery is limited. For example, the trajectory of the United Parkinson s Disease Rating Score (UPDRS— a measure of Parkinson s disease) has been described using Gompertz functions (20), which exhibit an asymptotic increase to a maximum score. However, over... 

Disease Rating Score (UPDRS), which has a natural maximum value. A maximum total of 199 points is possible on the UPDRS system. A score of 199 represents the worst possible disease status and a score of 0 indicates that the patient has no disability. In this setting, where the scoring system has an inherent maximum value, another exponential model can be considered. 

In the MPTP monkey model, like in humans, MPTP produces Parkinson-like symptoms that can be assessed by a modified Unified PD Rating Scale (UPDRS), the most commonly used tool for the evaluation of PD symptoms in humans. 

Of three Macaca mulatta monkeys implanted unilaterally into the striatum with five deposits of around 10000 cells on gelatin microcarriers each. Monkey 1 demonstrated about 80% improvement in the UPDRS that was sustained throughout the 8-month experiment. Monkey 2 demonstrated about a 60% improvement by 6 months post-implant and the third animal could not be used for efficacy assessments as the parkinsonism evoked by its MPTP lesions was of insufficient severity. This animal had bilateral surgery serving as a safety experiment. The results of this... 

Improvement in the primary outcome measure, the UPDRS Motor score in the practically defined OFF state (off all antiparkinsonian medication for at least 12 hours), was observed in all patients at 12 months and persisted until month 24. 

Total UPDRS scores for the group showed a mean improvement of 44% (51 points) in comparison to baseline over 12 months. Other secondary outcome measures include the UPDRS Motor ON (41%), UPDRS Activities of Daily Living (ADL) (OFF, 39% ON, 41%), and Schwab and England Physician Rated ADL (OFF, 41% ON, 9%). 

Fig. 14.5 Patient UPDRS Motor OFF" scores, primary outcome measure.

Table 14.1 Dyskinesias as rated in the UPDRS and Rush Dyskinesia Scale.

Fig. 14.6 Individual patient percent improvement in the primary outcome measure, UPDRS Motor "OFF scores, from baseline.

UPDRS Part IV scale. This may be interpreted as support for the hypothesis that continuous L-DOPA release as provided by implanted hRPE cells may partially reverse dyskinesias (ee Fig. 14.8). 

After 2 years of follow-up, it is not sufficient to look at UPDRS improvement alone. PD is a progressive disease and a mean deterioration by 10.65 points on the UPDRS scale is the expected disease progress per year [64]. Clinical experts recommend that in pilot studies for futility any deterioration in UPDRS by less than 7.45 points per year should be regarded as a potential clinically significant therapeutic effect. 

Patient UPDRS Motor OFF" scores, primary outcome Measure at baseline, baseline adjusted for natural disease course, d 12 and 24 months post-treatment. 

The dose of 325 000 cells administered unilaterally prompted substantial improvement of up to around 60% in UPDRS Motor Score in defined OFF in all six patients treated in a pilot study and no serious safety concerns. Transient signs of over-... 

Prior to signing an informed consent form, the patient must make use of at least 6 days reflection time. He or she wiU complete a total of five visits prior to surgery, three of them 2-day visits with UPDRS assessment in ON and in OFF. 

In brachytherapy, with the modern equipment now available, the clinically applied dose rates vary within large limits. The ICRU and the international brachytherapy community are recommending weighting factor, IIhdr and Updr, to compensate for the differences in dose rate for high dose-rate (HDR) and pulse dose-rate (PDR) brachytherapy, respectively. 

---